导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.17% | 1930/4773 |
| 近一周 | -1.78% | 721/5462 |
| 近一月 | -2.55% | 1308/5421 |
| 近一季 | -7.56% | 2449/5209 |
| 近半年 | 0.51% | 1148/4920 |
| 近一年 | 4.15% | 1785/4366 |
| 近两年 | 55.41% | 1329/2954 |
| 近三年 | 33.21% | 927/2253 |
| 成立以来 | 77.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.52% 3260/4961 |
17.13% 1492/5312 |
- - |
- - |
| 2025 | 23.72% 1851/4813 |
-0.14% 2078/3635 |
2.86% 1308/4076 |
18.94% 2221/4524 |
1.27% 1447/4813 |
| 2024 | 13.35% 1147/3463 |
1.88% 848/2808 |
-1.34% 1043/3014 |
15.00% 1847/3129 |
-1.94% 1893/3463 |
| 2023 | -9.37% 1153/2656 |
3.45% 1193/2280 |
-4.64% 1236/2385 |
-2.26% 647/2515 |
-6.01% 1594/2655 |
| 2022 | -17.64% 613/2207 |
-13.01% 683/1919 |
6.70% 628/2016 |
-11.19% 505/2113 |
-0.09% 1562/2208 |
| 2021 | 12.68% 379/1822 |
-0.21% 340/1255 |
14.08% 268/1330 |
-1.96% 551/1466 |
0.96% 1033/1822 |
| 2020 | 46.15% 213/1250 |
-6.28% 477/1028 |
19.40% 299/1067 |
16.88% 127/1164 |
11.74% 521/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信MSCI中国A股指数增强C VS. 长安沪深300非周期A(740101) |